Pregnancies and births after fertility preservation in cancer patients: Focus on breast cancer (notice n° 1613508)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02038cam a2200169 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260111052912.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gau, Sophie |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Pregnancies and births after fertility preservation in cancer patients: Focus on breast cancer |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 36 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Therapeutic advances in breast cancer have considerably improved survival in young patients, thus raising new issues concerning fertility and parenthood. Access to an oncofertility consultation prior to gonodotoxic treatments is now a legal requirement (bioethics laws of 2004 and 2011; Cancer Plan 2014–2019). Depending on the patient and the oncological context, cryopreservation of oocytes, embryos, or ovarian tissue may be discussed. However, data on pregnancies and births after fertility preservation show that the use of preserved gametes remains low. Even though the pregnancy rate is significantly lower after breast cancer, patients usually conceive spontaneously, and the use of assisted reproductive technologies (ART) remains moderate. Moreover, the oncological safety of posttreatment pregnancies is reassuring overall, even for hormone-dependent tumors, provided at least a two-year interval is observed after treatment. Particular attention should be paid to vascular obstetric complications (gestational hypertension, preeclampsia), especially in patients who have previously undergone chemotherapy. Breastfeeding is possible in most cases and does not increase the risk of recurrence. At present, there is no specific follow-up program for children born after fertility preservation for breast cancer. A program is currently underway in France to monitor the neurodevelopment of vulnerable children up to the age of seven. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bobrie, Angélique |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Médecine de la Reproduction | 27 | 3 | 2025-11-17 | p. 319-328 | 2650-8427 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-medecine-de-la-reproduction-2025-3-page-319?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-medecine-de-la-reproduction-2025-3-page-319?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux